Asahi Kasei Pharma enters into exclusive license agreement for anti-CX3CR1 Antibody EP News Bureau Dec 11, 2024 The anti-CX3CR1 antibody, currently in preclinical development, works by inhibiting CX3CR1, a receptor involved in immune cell…